Found: 100
Select item for more details and to access through your institution.
Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.
- Published in:
- 2018
- By:
- Publication type:
- Letter
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Non-European Union doctors in the National Health Service: why, when and how do they come to the United Kingdom of Great Britain and Northern Ireland?
- Published in:
- Human Resources for Health, 2007, v. 5, p. 1, doi. 10.1186/1478-4491-5-6
- By:
- Publication type:
- Article
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
- Published in:
- Cardiovascular Diabetology, 2020, v. 19, n. 1, p. 1, doi. 10.1186/s12933-020-01147-9
- By:
- Publication type:
- Article
Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.
- Published in:
- Neuroendocrinology, 2018, v. 106, n. 2, p. 148, doi. 10.1159/000473893
- By:
- Publication type:
- Article
Kisspeptin Restores Pulsatile LH Secretion in Patients with Neurokinin B Signaling Deficiencies: Physiological, Pathophysiological and Therapeutic Implications.
- Published in:
- Neuroendocrinology, 2013, v. 97, n. 2, p. 193, doi. 10.1159/000336376
- By:
- Publication type:
- Article
Hypothesis: Kisspeptin Mediates Male Hypogonadism in Obesity and Type 2 Diabetes.
- Published in:
- Neuroendocrinology, 2010, v. 91, n. 4, p. 302, doi. 10.1159/000299767
- By:
- Publication type:
- Article
A survey in India of doctors' knowledge, attitudes and practice regarding telemedicine and e-health.
- Published in:
- Journal of Telemedicine & Telecare, 2007, v. 13, n. 6, p. 322, doi. 10.1258/135763307781644924
- By:
- Publication type:
- Article
Neurokinin B Regulates Gonadotropin Secretion, Ovarian Follicle Growth, and the Timing of Ovulation in Healthy Women.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2016, p. 4313, doi. 10.1210/jc.2016-1202
- By:
- Publication type:
- Article
Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
- Published in:
- Diabetologia, 2018, v. 61, n. 10, p. 2155, doi. 10.1007/s00125-018-4702-3
- By:
- Publication type:
- Article
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
- Published in:
- Diabetologia, 2018, v. 61, n. 8, p. 1712, doi. 10.1007/s00125-018-4644-9
- By:
- Publication type:
- Article
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
- Published in:
- Diabetologia, 2018, v. 61, n. 7, p. 1522, doi. 10.1007/s00125-018-4630-2
- By:
- Publication type:
- Article
Bladder cancer in the EMPA-REG OUTCOME trial.
- Published in:
- 2017
- By:
- Publication type:
- Letter
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2775, doi. 10.1111/dom.14535
- By:
- Publication type:
- Article
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1886, doi. 10.1111/dom.14415
- By:
- Publication type:
- Article
Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 5, p. 1173, doi. 10.1111/dom.14326
- By:
- Publication type:
- Article
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 425, doi. 10.1111/dom.14234
- By:
- Publication type:
- Article
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2335, doi. 10.1111/dom.14158
- By:
- Publication type:
- Article
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1141, doi. 10.1111/dom.14015
- By:
- Publication type:
- Article
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1151, doi. 10.1111/dom.14017
- By:
- Publication type:
- Article
Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1207, doi. 10.1111/dom.13991
- By:
- Publication type:
- Article
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 631, doi. 10.1111/dom.13938
- By:
- Publication type:
- Article
Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 427, doi. 10.1111/dom.13945
- By:
- Publication type:
- Article
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 5, p. 1073, doi. 10.1111/dom.13645
- By:
- Publication type:
- Article
Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 1, p. 136, doi. 10.1111/dom.13496
- By:
- Publication type:
- Article
Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 9, p. 2200, doi. 10.1111/dom.13352
- By:
- Publication type:
- Article
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 9, p. 2190, doi. 10.1111/dom.13351
- By:
- Publication type:
- Article
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME<sup>®</sup> trial.
- Published in:
- European Heart Journal, 2020, v. 41, n. 2, p. 209, doi. 10.1093/eurheartj/ehz621
- By:
- Publication type:
- Article
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.
- Published in:
- European Heart Journal, 2019, v. 40, n. 34, p. 2907, doi. 10.1093/eurheartj/ehy677
- By:
- Publication type:
- Article
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
- Published in:
- Age & Ageing, 2019, v. 48, n. 6, p. 859, doi. 10.1093/ageing/afz096
- By:
- Publication type:
- Article
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
- Published in:
- Cardiovascular Diabetology, 2018, v. 17, p. 1, doi. 10.1186/s12933-018-0682-3
- By:
- Publication type:
- Article
Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
- Published in:
- American Journal of Hypertension, 2020, v. 33, n. 12, p. 1092, doi. 10.1093/ajh/hpaa073
- By:
- Publication type:
- Article
One-third of doctors completing specialist training in diabetes fail to secure a substantive consultant post: Young Diabetologists' Forum survey 2010.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
One-third of doctors completing specialist training in diabetes fail to secure a substantive consultant post: Young Diabetologists' Forum survey 2010.
- Published in:
- Clinical Medicine, 2012, v. 12, n. 3, p. 244, doi. 10.7861/clinmedicine.12-3-244
- By:
- Publication type:
- Article
Molecular clocks, type 2 diabetes and cardiovascular disease.
- Published in:
- Diabetes & Vascular Disease Research, 2008, v. 5, n. 2, p. 89, doi. 10.3132/dvdr.2008.015
- By:
- Publication type:
- Article
Waist circumference in type 2 diabetes: is routine measurement helpful?
- Published in:
- Diabetes & Vascular Disease Research, 2007, v. 4, n. 4, p. 375, doi. 10.3132/dvdr.2007.068
- By:
- Publication type:
- Article
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- Published in:
- 2019
- By:
- Publication type:
- journal article
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
- Published in:
- 2019
- By:
- Publication type:
- Letter
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.
- Published in:
- Clinical Kidney Journal, 2021, v. 14, n. 9, p. 2136, doi. 10.1093/ckj/sfab104
- By:
- Publication type:
- Article
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.
- Published in:
- Clinical Kidney Journal, 2021, v. 14, p. 226, doi. 10.1093/ckj/sfaa225
- By:
- Publication type:
- Article
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
- Published in:
- Clinical Kidney Journal, 2020, v. 13, n. 4, p. 722, doi. 10.1093/ckj/sfz009
- By:
- Publication type:
- Article
Pertinence of Textile-Based Energy Harvesting System for Biomedical Applications.
- Published in:
- Journal of Nanomaterials, 2022, p. 1, doi. 10.1155/2022/7921479
- By:
- Publication type:
- Article